<DOC>
	<DOCNO>NCT02887443</DOCNO>
	<brief_summary>This phase I open label study conduct assess potential pharmacokinetic interaction RaxoneÂ® midazolam healthy male volunteer</brief_summary>
	<brief_title>A Study Assess Potential Pre-systemic Inhibition CYP3A Idebenone Using Midazolam Substrate</brief_title>
	<detailed_description />
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Healthy male age 18 55 year . 2 . A Body Mass Index ( BMI ) 1830 . BMI = Body weight ( kg ) / Height ( ) 2 . 3 . Male subject willing use acceptable effective contraceptive measure entire duration study participation . 4 . No clinically significant abnormal serum biochemistry , haematology urine examination value . 5 . A negative urinary test drug abuse alcohol breath screen . A positive alcohol test may repeat discretion Investigator . 6 . Negative HIV Hepatitis B C result . 7 . No clinically significant abnormality 12 lead electrocardiogram ( ECG ) . 8 . No clinically significant abnormality blood pressure , pulse oral temperature . 9 . No allergy sensitivity midazolam , idebenone excipients . 10 . No current past medical condition might significantly affect pharmacokinetic pharmacodynamic response midazolam . 11 . Subject must available complete study ( include followup visit ) . 12 . Subject must satisfy medical examiner fitness participate study . 13 . Subject must provide write informed consent participate study . 14 . Covered Health Insurance System and/or compliance recommendation National Law force relate biomedical research . 1 . A clinically significant history gastrointestinal disorder likely influence drug absorption . 2 . Use medication ( prescription OTC , include health supplement herbal remedy , except paracetamol , within 2 week 5 halflives ( whichever longer ) prior first dose trial medication . 3 . Use medication know induce inhibit enzyme within CYP3A system within 28 day Day 1 , grapefruit within 7 day Day 1 4 . Evidence renal , hepatic dysfunction , cardiovascular metabolic dysfunction . 5 . History obstructive sleep apnoea syndrome . 6 . History significant drug allergy include benzodiazepine . 7 . A clinically significant history drug alcohol abuse . 8 . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . 9 . Participation clinical trial New Chemical Entity within previous 3 month Marketed Product within previous 30 day ( 5 time halflife , whichever long ) . 10 . Donation 450 mL blood within previous 3 month . 11 . Smoking use tobacco product substitute within previous 6 month , determine Screening visit . 12 . Need administrative legal supervision . 13 . Subject would receive 4500 euros indemnity participation biomedical research within 12 month , include indemnity present study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>